Tricuspid atresia medical therapy
|
Tricuspid atresia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenarios |
|
Case Studies |
|
Tricuspid atresia medical therapy On the Web |
|
American Roentgen Ray Society Images of Tricuspid atresia medical therapy |
|
Risk calculators and risk factors for Tricuspid atresia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2]Keri Shafer, M.D. [3] Priyamvada Singh, MBBS [4]; Assistant Editor-In-Chief: Kristin Feeney, B.S. [5]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
The mainstay of therapy for the cyanotic neonate with severe pulmonary stenosis and small-sized VSD is using prostaglandin E1 (PGE1) for keeping patency of ductus arteriosis. The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.
Medical Therapy
- The mainstay of therapy for the cyanotic neonate with severe pulmonary stenosis and small-sized VSD is using prostaglandin E1 (PGE1) for keeping patency of ductus arteriosis.[1]
- The mainstay of therapy for heart failure symptoms is using diuretic for reduction of congestion and then starting ACEI.
References
- ↑ Akkinapally, Smita; Hundalani, Shilpa G; Kulkarni, Madhulika; Fernandes, Caraciolo J; Cabrera, Antonio G; Shivanna, Binoy; Pammi, Mohan (2018). "Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD011417.pub2. ISSN 1465-1858.